Abstract
We present a 42-year-old woman with no history of diabetes or glucose intolerance who had a 5-year history of ulcerative necrobiosis lipoidica (NL). Despite failure of multiple medications, she experienced clearing of her ulcers after her treatment was changed to ustekinumab. We discuss our patient’s disease course and elaborate upon mechanistic reasons for her improvement related to ustekinumab therapy.
| Original language | English (US) |
|---|---|
| Journal | Dermatology Online Journal |
| Volume | 23 |
| Issue number | 7 |
| State | Published - 2017 |
Fingerprint
Keywords
- Granulomatous dermatitis
- IFNγ
- Macrophage
- Necrobiosis lipoidica
- Th1
- Ustekinumab
ASJC Scopus subject areas
- Dermatology
Cite this
Ustekinumab to target granulomatous dermatitis in recalcitrant ulcerative necrobiosis lipoidica : Case report and proposed mechanism. / Hassoun, Lauren A.; Sivamani, Raja K; Sharon, Victoria R.; Silverstein, Marc; Burrall, Barbara A; Tartar, Danielle.
In: Dermatology Online Journal, Vol. 23, No. 7, 2017.Research output: Contribution to journal › Letter
}
TY - JOUR
T1 - Ustekinumab to target granulomatous dermatitis in recalcitrant ulcerative necrobiosis lipoidica
T2 - Case report and proposed mechanism
AU - Hassoun, Lauren A.
AU - Sivamani, Raja K
AU - Sharon, Victoria R.
AU - Silverstein, Marc
AU - Burrall, Barbara A
AU - Tartar, Danielle
PY - 2017
Y1 - 2017
N2 - We present a 42-year-old woman with no history of diabetes or glucose intolerance who had a 5-year history of ulcerative necrobiosis lipoidica (NL). Despite failure of multiple medications, she experienced clearing of her ulcers after her treatment was changed to ustekinumab. We discuss our patient’s disease course and elaborate upon mechanistic reasons for her improvement related to ustekinumab therapy.
AB - We present a 42-year-old woman with no history of diabetes or glucose intolerance who had a 5-year history of ulcerative necrobiosis lipoidica (NL). Despite failure of multiple medications, she experienced clearing of her ulcers after her treatment was changed to ustekinumab. We discuss our patient’s disease course and elaborate upon mechanistic reasons for her improvement related to ustekinumab therapy.
KW - Granulomatous dermatitis
KW - IFNγ
KW - Macrophage
KW - Necrobiosis lipoidica
KW - Th1
KW - Ustekinumab
UR - http://www.scopus.com/inward/record.url?scp=85025705014&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85025705014&partnerID=8YFLogxK
M3 - Letter
C2 - 29469709
AN - SCOPUS:85025705014
VL - 23
JO - Dermatology Online Journal
JF - Dermatology Online Journal
SN - 1087-2108
IS - 7
ER -